GSK and Moderna Settle Patent Fight Over COVID and RSV Shots

GSK and Moderna have settled every patent lawsuit between them over Moderna's COVID-19 vaccines Spikevax and mNEXSPIKE and its RSV shot mResvia, the companies announced on Oct. 6. The deal closes a two-front legal fight that GSK opened in 2024 over the lipid nanoparticle technology at the heart of messenger RNA vaccines.

The terms are unusually clean. Moderna said in a press release that it settled GSK's patent litigation in the US and Europe on October 28, and that the two companies "granted patent cross-licenses in the field of infectious disease and are not obligated to make payments of any kind in connection with such licenses."

That single sentence carries the whole deal. Each side keeps selling its products. Neither writes a check. Neither admits fault on the underlying infringement claims.

What happens in court?

The companies asked a Delaware federal court on Oct. 6 to dismiss GSK's US infringement claims with prejudice. That phrase matters. A dismissal with prejudice bars GSK from ever refiling those claims in that court. The dispute over Spikevax, mNEXSPIKE and mResvia is finished, not paused.

A GSK spokesperson framed the settlement as a practical step, saying the company was "pleased to have reached a resolution that provides clarity for both companies and enables continued focus on advancing innovation for patients."

What was the fight about?

GSK sued Moderna in 2024. The target was not the mRNA itself but the lipid nanoparticles wrapped around it. Those particles transport fragile messenger RNA into the human body without it degrading first. GSK claimed patents on that delivery technology. Moderna's Spikevax, its updated COVID vaccine mNEXSPIKE, and its respiratory syncytial virus shot mResvia all depend on it.

The settlement removes the legal cloud over three commercial products in one stroke, and it does so without any royalty stream flowing to GSK — a sharp contrast with what patent holders typically seek in vaccine litigation.

Does the wider patent war continue?

Yes. GSK filed a similar lawsuit against Pfizer and BioNTech over their COVID-19 vaccine earlier that same year, and that case is still ongoing.

The GSK-Moderna settlement also leaves intact a broader web of US court cases involving Pfizer, BioNTech and Moderna over patent royalties for COVID vaccine technology. Moderna itself sued Pfizer in 2022, adding its own claim to the pile.

What does the cross-license signal?

The scope of the license tells its own story. It covers the field of infectious disease, which is wider than the three products named in the dispute. That breadth suggests both companies valued legal certainty across their pipelines more than a one-off payout or a court verdict.

For Moderna, the settlement clears the path for its newest products, mNEXSPIKE and mResvia, without a royalty drag on future sales. For GSK, it ends a case where the payoff was always uncertain, while its parallel claim against Pfizer and BioNTech keeps a larger bet alive.

The next marker for the industry will be the outcome of the Pfizer-BioNTech litigation. If that case reaches a verdict or settlement on different terms, it will test whether the GSK-Moderna no-payment model becomes the template for mRNA patent disputes, or the exception.